Sign in

CIK 0001826457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Monte Rosa Therapeutics, Inc.

Sign in to watch
Ticker
GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 617-949-2643
Business address
321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
Former names
Monte Rosa Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$137
in 1 filing

Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Bowen Matthew −$137 Principal Accounting Officer sold <1% of stake
Date Insider Transaction Shares Price Value Owned after
2021-06-23 Warmuth Markus Grant or award · Stock Option (Right to Buy) +141,623 141,623
2021-06-23 Mayweg Alexander Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-04-12 Wallace Owen B. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +387,069 387,069
2021-04-12 Tamboli Ajim Chief Financial Officer Grant or award · Stock Option (Right to Buy) +100,938 100,938
2021-04-12 Blackwell Kimberly Director Grant or award · Stock Option (Right to Buy) +7,081 7,081
2021-04-12 Siu Christine Director Grant or award · Stock Option (Right to Buy) +7,081 7,081
2021-04-12 Warmuth Markus Grant or award · Stock Option (Right to Buy) +538,517 538,517
2021-03-11 Bolzon Bradley J PhD Director Grant or award · Series C convertible preferred stock +2,699,328 $2.96 $8.0M 2,699,328
2021-02-24 Bolzon Bradley J PhD Director Grant or award · Series B convertible preferred stock +1,500,000 $2.00 $3.0M 3,000,000
2021-02-24 Bolzon Bradley J PhD Director Grant or award · Series B convertible preferred stock +2,075,000 $2.00 $4.2M 4,150,000

Page 16 of 16 · 310 trades